BACKGROUND: Since the primary routes of human immunodeficiency type 1 (HIV-1) infection are across mucosal barriers, a randomized trial of canarypox virus-based vectors was conducted in 84 individuals, with delivery of vaccine by mucosal routes, and was accompanied by a detailed analysis of humoral, cellular, and mucosal immune responses. METHODS: Over the course of 6 months, HIV-1-specific (vCP 205) and rabies (vCP 65) canarypox virus vectors were delivered systemically and/or mucosally into the nose, mouth, vagina, or rectum in a 4-dose schedule, followed by 2 doses of HIV-1 MN recombinant glycoprotein (rgp) 120 or subunit rabies vaccine administered by the intramuscular route. RESULTS: Administration of vaccine and collection of samples were well tolerated. Serum IgG HIV-1-specific antibodies to rgp120 were rarely seen after either systemic or mucosal delivery of canarypox virus vaccine. In contrast, serum IgG rabies and canarypox antibodies were detected in all individuals after systemic, but rarely after mucosal, delivery of vaccine. Suggestions of mucosal recognition of HIV-1 antigen included a cytotoxic T lymphocyte response in 4 of 8 individuals after administration of vaccine by the intrarectal route and a limited immunoglobulin A response at the same site. CONCLUSIONS: Each of the routes of vaccine administration was feasible in the context of a phase 1 study with motivated individuals. However, with the doses and routes of administration used, canarypox virus was not an effective mucosal immunogen.
RCT Entities:
BACKGROUND: Since the primary routes of humanimmunodeficiency type 1 (HIV-1) infection are across mucosal barriers, a randomized trial of canarypox virus-based vectors was conducted in 84 individuals, with delivery of vaccine by mucosal routes, and was accompanied by a detailed analysis of humoral, cellular, and mucosal immune responses. METHODS: Over the course of 6 months, HIV-1-specific (vCP 205) and rabies (vCP 65) canarypox virus vectors were delivered systemically and/or mucosally into the nose, mouth, vagina, or rectum in a 4-dose schedule, followed by 2 doses of HIV-1 MN recombinant glycoprotein (rgp) 120 or subunit rabies vaccine administered by the intramuscular route. RESULTS: Administration of vaccine and collection of samples were well tolerated. Serum IgG HIV-1-specific antibodies to rgp120 were rarely seen after either systemic or mucosal delivery of canarypox virus vaccine. In contrast, serum IgG rabies and canarypox antibodies were detected in all individuals after systemic, but rarely after mucosal, delivery of vaccine. Suggestions of mucosal recognition of HIV-1 antigen included a cytotoxic T lymphocyte response in 4 of 8 individuals after administration of vaccine by the intrarectal route and a limited immunoglobulin A response at the same site. CONCLUSIONS: Each of the routes of vaccine administration was feasible in the context of a phase 1 study with motivated individuals. However, with the doses and routes of administration used, canarypox virus was not an effective mucosal immunogen.
Authors: Nina D Russell; Barney S Graham; Michael C Keefer; M Juliana McElrath; Steve G Self; Kent J Weinhold; David C Montefiori; Guido Ferrari; Helen Horton; Georgia D Tomaras; Sanjay Gurunathan; Lynn Baglyos; Sharon E Frey; Mark J Mulligan; Clayton D Harro; Susan P Buchbinder; Lindsey R Baden; William A Blattner; Beryl A Koblin; Lawrence Corey Journal: J Acquir Immune Defic Syndr Date: 2007-02-01 Impact factor: 3.731
Authors: F Javier Ibarrondo; Peter A Anton; Marie Fuerst; Hwee L Ng; Johnson T Wong; Jose Matud; Julie Elliott; Roger Shih; Mary Ann Hausner; Charles Price; Lance E Hultin; Patricia M Hultin; Beth D Jamieson; Otto O Yang Journal: J Virol Date: 2005-04 Impact factor: 5.103
Authors: Kaustuv Banerjee; Elizabeth Michael; Dirk Eggink; Thijs van Montfort; Amanda B Lasnik; Kenneth E Palmer; Rogier W Sanders; John P Moore; Per Johan Klasse Journal: AIDS Res Hum Retroviruses Date: 2011-07-27 Impact factor: 2.205
Authors: John P Bilello; Julieta M Manrique; Young C Shin; William Lauer; Wenjun Li; Jeffrey D Lifson; Keith G Mansfield; R Paul Johnson; Ronald C Desrosiers Journal: J Virol Date: 2011-09-07 Impact factor: 5.103
Authors: B S Graham; R C Kines; K S Corbett; J Nicewonger; T R Johnson; M Chen; D LaVigne; J N Roberts; N Cuburu; J T Schiller; C B Buck Journal: Mucosal Immunol Date: 2010-06-16 Impact factor: 7.313